



## **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

### **Listing of claims:**

- 1-45. (Canceled).
46. (New) A method for producing a monaparamunity inducer, comprising:
  - (a) isolating a myxomavirus from infected tissue of a rabbit;
  - (b) adapting the virus to a permissive cell system; and
  - (c) passaging the adapted virus to generate an attenuated myxomavirus that induces monaparamunity.
47. (New) The method of claim 46, wherein the adaptation of the virus to a permissive cell system comprises culturing the virus on a chorioallantoic membrane of incubated chicken eggs.
48. (New) The method of claim 46, wherein the passaging of the adapted virus comprises passaging the virus in Vero monkey cells.
49. (New) The method of claim 48, wherein the virus is passaged at least 80 passages in Vero monkey cells.
50. (New) The method of claim 48, wherein the virus is passaged at least 120 passages in Vero monkey cells.
51. (New) The method of claim 48, wherein the virus is passaged at least 150 passages in Vero monkey cells.
52. (New) The method of claim 46, wherein the passaging of the adapted virus comprises passaging the virus in an AVIVER cell culture.

53. (New) The method of claim 52, wherein the virus is passaged at least 10 passages in an AVIVER cell culture.

54. (New) The method of claim 52, wherein the virus is passaged at least 25 passages in an AVIVER cell culture.

55. (New) The method of claim 52 wherein the virus is passaged at least 50 passages an AVIVER cell culture.

56. (New) An attenuated myxomavirus obtained by the method of claim 46.

57. (New) The attenuated myxomavirus of claim 56, wherein the attenuated myxomavirus has the deposit number ECACC 03121801.

58. (New) A method for inducing monoparamunity in a host comprising:

- (a) providing an attenuated myxomavirus; and
- (b) administering the attenuated myxomavirus to a host.

59. (New) The method of claim 58, wherein the attenuated myxomavirus comprises a mutation in a viral gene encoding a cytokine receptor selected from IFN $\alpha$ -R, IFN $\gamma$ -R, TNF-R, IL-1-R, IL-2-R, IL-6-R, and IL-12-R.

60. (New) The method of claim 58, wherein the attenuated myxomavirus has a deletion of the coding gene segments for the viral genes encoding the cytokine receptors IFN $\alpha$ -R, IFN $\gamma$ -R, TNF-R, IL-1-R, IL-2-R, IL-6-R, and IL-12-R.

61. (New) The method of claim 58, wherein the myxomavirus is inactivated with beta-propiolactone.

62. (New) The method of claim 61, wherein the beta-propiolactone is at a concentration of 0.01%-1%.

63. (New) The method of claim 61, wherein the beta-propiolactone is at a concentration of 0.5%.

64. (New) The method of claim 58, wherein the inactivated, attenuated myxomavirus is administered via the skin or mucous membrane of the host.

65. (New) The method of claim 58, wherein the inactivated, attenuated myxomavirus is administered in tablet form.

66. (New) A pharmaceutical composition for inducing monoparamunity comprising an attenuated myxomavirus of claim 56.

67. (New) The pharmaceutical composition of claim 66, wherein the attenuated myxomavirus has a mutation in a viral gene encoding a cytokine receptor selected from IFN $\alpha$ -R, IFN $\gamma$ -R, TNF-R, IL-1-R, IL-2-R, IL-6-R, and IL-12-R.

68. (New) The pharmaceutical composition of claim 67, wherein the mutation is a deletion.

69. (New) The pharmaceutical composition of claim 66, wherein the attenuated myxomavirus has the deposit number ECACC 03121801.